Drug · CHEMBL689
MANNITOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MANNITOL. Drugs and targets, record CHEMBL689. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL689
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Aridol kit, Bronchitol, Diosmol, Mannitol component of sorbitol-, Osmitrol, Resectisol
- ChEMBL
- Other names
Cordycepic acid, Crystalline mannitol extra-fine, Crystalline mannitol fine, Crystalline mannitol standard, D-(-)-mannitol, D-mannitol, E-421, E421, INS NO.421, INS-421, Isomalt impurity, mannitol-, Manna sugar, Mannite, Mannitol 200, Mannitol 2080, Mannitol 25, Mannitol 300, Mannitol 35, Mannitol 60, Mannitol m300, Mannitol, d-, Mannitolum, Mannogem 2080, NSC-407017, Pearlitol 160 c, Pearlitol 200 sd, Pearlitol 25 c, Pearlitol 300 dc, Pearlitol 50 c
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 34 diseases, from ATC, DailyMed, EMA Human Drugs and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases34
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 34Source Open Targets
See all 34 diseasesTrials107
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04759885 | Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep® | Phase 2/3 | 886 | 2025-12-08 | mannitol | Its name | ClinicalTrials.gov |
| NCT00669331 | Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis | Phase 3 | 485 | 2016-04-29 | mannitol | Its name | ClinicalTrials.gov |
| NCT02134353 | A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects | Phase 3 | 423 | 2020-09-03 | mannitol | Its name | ClinicalTrials.gov |
| NCT00630812 | Long Term Administration of Inhaled Mannitol in Cystic Fibrosis | Phase 3 | 318 | 2020-10-09 | mannitol | Its name | ClinicalTrials.gov |
| NCT01606787 | Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes | Phase 3 | 210 | 2018-06-12 | mannitol | Its name | ClinicalTrials.gov |
| NCT02677623 | Evaluation of Ureteral Patency in the Post-indigo Carmine Era | Phase 4 | 140 | 2019-05-30 | mannitol | Its name | ClinicalTrials.gov |
| NCT01520207 | Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension | Phase 2 | 52 | 2017-10-19 | mannitol | Its name | ClinicalTrials.gov |
| NCT02760862 | Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache | Phase 4 | 50 | 2020-08-25 | mannitol | Its name | ClinicalTrials.gov |
| NCT04534465 | Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements. | Phase 4 | 50 | 2020-11-12 | mannitol | Its name | ClinicalTrials.gov |
| NCT05740618 | Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis | Phase 4 | 14 | 2026-01-07 | mannitol | Its name | ClinicalTrials.gov |
1 to 10 of 107
See all 107 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phase III: NTC015 Selected Dose vs Phase III: 2L PEG ASC (Moviprep®): Phase III - Non-inferiority: Proportion of Patients With Change of Vital Signs From Baseline and During Colonoscopy | 2 of 343 | 1 of 347 | 690 | NCT04759885 | Trial comparisons |
| Mannitol vs Control: Safety Profile - Sputum Microbiology | 81 of 233 | 81 of 228 | 461 | NCT00669331 | Trial comparisons |
| Mannitol vs Control: Safety Profile - Hematology | 13 of 233 | 5 of 228 | 461 | NCT00669331 | Trial comparisons |
| Mannitol vs Control: serious adverse events | 43 of 233 | 51 of 228 | 461 | NCT00669331 | Trial comparisons |
| Experimental Arm A vs Arm B - Control: The Incidence of Pulmonary Exacerbations | 28 of 209 | 29 of 214 | 423 | NCT02134353 | Trial comparisons |
| Experimental Arm A vs Arm B - Control: deaths from any cause | 0 of 207 | 1 of 213 | 420 | NCT02134353 | Trial comparisons |
| Experimental Arm A vs Arm B - Control: serious adverse events | 31 of 207 | 29 of 213 | 420 | NCT02134353 | Trial comparisons |
| Mannitol 400mg vs Control: deaths from any cause | 0 of 184 | 1 of 121 | 305 | NCT00630812 | Trial comparisons |
| Mannitol 400mg vs Control: serious adverse events | 31 of 184 | 30 of 121 | 305 | NCT00630812 | Trial comparisons |
| Mannitol Arm vs Placebo Arm: deaths from any cause | 0 of 101 | 2 of 98 | 199 | NCT01606787 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials57
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL689
GET https://conductscience.org/api/drugs/v1/CHEMBL689/diseases?page=2